Biodistribution of free Francium-221 and Bismuth-213 in Tumour-bearing SCID mice after successful development of Actinium-225/Francium-221 radionuclide generator Set-up.

ABSTRACT:

Purpose

Despite the clinical evidence of actinium-225 (²²⁵Ac)-based targeted alpha therapies (TαT) efficacy, optimized treatment regimens are needed to improve overall clinical response rates and decrease toxicities. The nuclear recoil effect of ²²⁵Ac and its resulting daughter nuclides have been hypothesized to contribute to non-targeted damage. However, a lack of generator concepts for radionuclidically pure francium-221 (²²¹Fr), involvement of strong acids for elution, and its short half-life (4.8 min), has limited in vivo studies. Here, we report on a successful application of an ²²⁵Ac/²²¹Fr generator concept and the in vivo distribution of ²²¹Fr and bismuth-213 (²¹³Bi).

Methods

The immobilizati

SUBMITTER: Zitzmann-Kolbe S 

PROVIDER: S-EPMC12660422 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature